
Winter 2003
Shawn T. Estrem, Ph.D.
Eli Lilly and Company
Andrew Brooks, Ph.D. and Agnes Viale, Ph.D.
University of Rochester and Memorial Sloan-Kettering Cancer Center
Yunsheng Hsieh, Ph.D., Jean-Marc Brisson, & Ganfeng Wang
Drug Metabolism and Pharmacokinetics Department, Schering-Plough Research Institute
Joseph A. Turpin1 & Douglas Perry, Ph.D.2
1Lilly Research Laboratories; Eli Lilly and Company, Inc.
2Indiana University School of Informatics
Brian Scarlett
Particle Engineering Research Center, University of Florida
Sarah K. Doshna
Bristol-Myers Squibb
Jeffrey J. Blumenstein, Ph.D.
Pfizer Inc.
Michael R. DeFelippis, Ph.D.
Eli Lilly and Company
R.D. McDowall, Ph.D.
McDowall Consulting
Carl A. Anderson, Ph.D.
Duquesne University Center for Pharmaceutical Technology
Anthony J. Hickey, Ph.D.
School of Pharmacy, University of North Carolina at Chapel Hill
Dirk L. Teagarden, Ph.D.
Pfizer Global Pharmaceutical Sciences, Department of Sterile Products Development
Wei Zheng, Ph.D.1 and Laszlo Kiss, Ph.D.2
1Department of Automated Biotechnology and 2Department of Molecular Pharmacology, Pennsylvania
Nathaniel Milton, Ph.D., Abira Pyne, Ph.D., Dinesh Mishra, Ph.D., and Lian Yu, Ph.D.
Eli Lilly and Company
Fangling Needham, Ph.D., and John Faber, Ph.D.
The International Centre for Diffraction Data (ICDD)